Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Nycomed hails progress in second quarter of 2010

Nycomed hails progress in second quarter of 2010

18th August 2010

Nycomed has expressed satisfaction with its progress towards a number of its financial and clinical goals in the second quarter of 2010.

The pharmaceutical company published a total net turnover figure of 786.5 million euros (648.9 million pounds), which was roughly level with the corresponding period of last year.

According to the firm, strong sales of its key products, as well as its growing presence in emerging markets, have been able to counteract the sales impact of the patent expiry of the drug pantoprazole.

Moreover, it has made significant progress in securing clearance for the release of its new drug Daxas, which it is in the process of launching in the UK and Germany.

The treatment has proven its efficacy as an oral therapy for chronic obstructive pulmonary disease in clinical trials and is said to be the first drug of its kind in a new class.

Hakan Bjorklund, chief executive officer of Nycomed, said: "We expect further growth in our portfolio of key products and the introduction of Daxas in several markets. Efforts to enhance our emerging market presence … are well underway."ADNFCR-8000103-ID-800029557-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.